A Look At Akeso (SEHK:9926) Valuation After IND Clearance For Trispecific Antibody AK150

Akeso (SEHK:9926) is back in focus after announcing that its trispecific antibody AK150 has received IND clearance from China’s NMPA, clearing the way for clinical trials in advanced solid tumors. See our latest analysis for Akeso. The AK150 IND clearance, together with recent cervical cancer data for cadonilimab and the GBM collaboration announcement, has coincided with a 5.81% 1 day share price return and a 12.44% 7 day share price return at a current share price of HK$116.6. The 1 year total shareholder return of 62.96% and 3 year total shareholder return of around 2.7x point to momentum that has built over time rather than just in the past month. If you are looking beyond a single biotech name, this is a good moment to scan for other healthcare names using AI in drug development through the 123 healthcare AI stocks So with Akeso posting a 63% 1 year total return, trading at HK$116.6, and sitting at roughly a 48% discount to one intrinsic value estimate, are you looking at an underappreciated growth story, or a stock where the market is already pricing in what comes next? Most Popular Narrative: 32.4% Undervalued Akeso's most followed narrative suggests a fair value of HK$172.49 per share versus the current HK$116.6, placing the latest IND news in the context of a much higher long term potential. The company's strong R&D pipeline, including advanced bispecific antibodies and ADC candidates, provides a foundation for long-term growth, setting the stage for potential increases in net margins as products move from development to commercialization. Read the complete narrative. Want to see what kind of revenue ramp and margin shift that pipeline implies? The narrative is based on aggressive top line growth, rising profitability and a premium future earnings multiple that many investors usually associate with market leaders. Result: Fair Value of HK$172.49 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this upbeat narrative can unravel quickly if operating losses persist, or if key drugs like cadonilimab and ivonescimab face pricing pressure or clinical setbacks. Find out about the key risks to this Akeso narrative. Another Way To Look At Akeso’s Valuation The popular narrative leans on a fair value of HK$172.49 per share, yet Akeso’s P/S ratio of 37.7x tells a different story. It is far above the Hong Kong Biotechs industry at 13.4x, the peer average at 21.8x, and even the fair ratio of 17.2x. This suggests that a lot of success is already priced in. So is the real risk here missing upside, or overpaying for growth that might take longer to arrive? See what the numbers say about this price — find out in our valuation breakdown. Next Steps The mixed messages on valuation and growth potential make Akeso a stock you need to assess for yourself, using the same data behind this article. To understand what the market is currently rewarding, take a closer look at the 2 key rewards Ready for more investment ideas? If Akeso has caught your attention, do not stop here. Use the same tools to spot other opportunities that might suit your goals and risk comfort. Hunt for quality at a discount by scanning companies that line up in the 227 high quality undervalued stocks. Target resilient balance sheets and steadier fundamentals by reviewing the solid balance sheet and fundamentals stocks screener (379 results). Search for under the radar prospects before the crowd catches on by checking the screener containing 583 high quality undiscovered gems. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.